Tags : First Half

Biotech COVID-19

Sanofi Anticipates the Approval of its COVID-19 Vaccine by First

Shots: Sanofi divulges in its virtual R&D day that the company is anticipating initiation of P-I/II study evaluating the recombinant protein-based​ vaccine candidate (baculovirus), developing in collaboration with GSK while expecting the complete approval in H1’20 Sanofi also highlights capabilities, platforms, and expertise in disease pathways to deliver potentially transformative treatments to patients Additionally, Sanofi […]Read More